Skip to Content
Get key facts and figures about chronic dry eye

Rimexolone ophthalmic Pregnancy and Breastfeeding Warnings

Rimexolone ophthalmic is also known as: Vexol

Medically reviewed on July 13, 2018

Rimexolone ophthalmic Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

Animal studies have shown this drug to be teratogenic and embryogenic. There are no adequate and well-controlled studies in pregnant women.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Rimexolone ophthalmic Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Vexol (rimexolone ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.

References for breastfeeding information

  1. "Product Information. Vexol (rimexolone ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide